echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Amjin China began laying off workers last month

    Amjin China began laying off workers last month

    • Last Update: 2021-03-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    recently, news broke that Amjin China began laying off workers last month.Sources revealed that Amjin China this time for the first time to lay off staff, its lay-off of the product line staff who failed to enter the national health care negotiations.It is reported that Amjin twice entered the Chinese market and withdrew. In 2018, Anjin re-entered China, and is currently promoting two product lines in China -Eloyu single resistanceJanuary 2019, Reegis was approved for use in adult patients with atherosclerosis cardiovascular disease.

    the solution of the anti-injectionIn May 2019, Anjindi Shudane anti-injection (commodity name: Angarvi) was officially approved in China for the treatment of osteoblastoma. On June 30, 2020, Baiji Shenzhou announced the commercialization of the drug in China,In June 2020, Anjindi Shu single anti-injection (60mg) (commodity name: Proli) was officially listed in China for the treatment of osteoporosis in postmenopaediopautia women.Among them, by Baiji Shenzhou commercialized drug Deshu single anti-injection into the national talks, and successfully shortlisted for the medical insurance directory, the adaptive disorder is: non-surgical removal or surgical removal may lead to severe dysfunction of osteoblastoma patients.And the product line that failed to enter the health insurance will be in the form of regional integration of layoffs, mainly for the outer market. Low-performing employees are advised to quit directly, and some high positions are removed directly. It is understood that the integration model in the region cut more than 40 positions, giving employees part of the internal transfer opportunities, but not many.In addition, the company did not provide any compensation for the layoffs. (Sina Pharmaceutical News)
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.